SCHIZO'TRAUMA: Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology

Sponsor
Centre Hospitalier Universitaire de Saint Etienne (Other)
Overall Status
Recruiting
CT.gov ID
NCT03355781
Collaborator
(none)
48
1
37.6
1.3

Study Details

Study Description

Brief Summary

Childhood trauma is known as a vulnerability factor in schizophrenia. In healthy volunteers, these adversities are linked to a decrease of grey matter of the brain, similar to those observed in schizophrenia.

In a previous study based on Voxel-Based Morphometry (VBM), including 21 schizophrenic patients and 30 healthy volunteers, the investigators shown a negative correlation between emotional neglect (important dimension in childhood trauma) and grey matter decrease. This strong correlation was significantly higher in schizophrenic patients than in healthy volunteers, suggesting a higher genetic predisposition to environmental factors in schizophrenic people.

Currently, interaction between genetic predisposition and environmental stress factors is the major model for understanding in schizophrenia. In order to analyze both effects on human body, particularly on brain, several studies currently focus on the product of genetic expression, the ribonucleic acid (ARN).

The purpose of this study is to provide an explanatory model of links between childhood trauma, candidate gene for schizophrenia expression, cerebral morphology and schizophrenic symptomatology. Using conceptual framework of stress vulnerability, structural equation modeling (SEM) will allow testing causal link between these different variables.

Condition or Disease Intervention/Treatment Phase
  • Device: magnetic resonance imaging (MRI)
  • Procedure: Blood sample
  • Other: Clinical psychiatric evaluation

Study Design

Study Type:
Observational
Anticipated Enrollment :
48 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology. SCHIZO' TRAUMA
Actual Study Start Date :
Nov 14, 2018
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Jan 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Schizophrenic patients

Patients will have clinical psychiatric evaluation, brain imaging and blood sample

Device: magnetic resonance imaging (MRI)
brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity

Procedure: Blood sample
27,5 ml of blood sample : genetic analysis and biobank

Other: Clinical psychiatric evaluation
Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)

Related volunteers (first degree relative of patient)

Related volunteers will have clinical psychiatric evaluation, brain imaging and blood sample

Device: magnetic resonance imaging (MRI)
brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity

Procedure: Blood sample
27,5 ml of blood sample : genetic analysis and biobank

Other: Clinical psychiatric evaluation
Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)

Healthy volunteers

Healthy volunteers will have clinical psychiatric evaluation, brain imaging and blood sample

Device: magnetic resonance imaging (MRI)
brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity

Procedure: Blood sample
27,5 ml of blood sample : genetic analysis and biobank

Other: Clinical psychiatric evaluation
Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)

Outcome Measures

Primary Outcome Measures

  1. Childhood Trauma Questionnaire (CTQ) for childhood trauma. [5 days]

    development of an etiopathogenic model characteristic of schizophrenia Childhood Trauma Questionnaire : to assess five types of childhood trauma : Emotional neglect physical abuse emotional abuse physical neglect sexual abuse Each item being rated in 5 answer choice from 1 to 5 (never, rarely, sometimes, often or very often)

  2. Quantitative measurement of RNAs [5 days]

    development of an etiopathogenic model characteristic of schizophrenia

  3. Voxel-based morphometry (VBM) for total gray matter [5 days]

    development of an etiopathogenic model characteristic of schizophrenia

  4. Voxel-based morphometry (VBM) for regional gray matter density. [5 days]

    development of an etiopathogenic model characteristic of schizophrenia

Secondary Outcome Measures

  1. Connectivity in the cortico-limbic circuit [5 days]

  2. Volumetry of the brain [5 days]

  3. Correlation of BOLD activity in the cortico-limbic circuit in patients with patients with symptomatic variables [5 days]

    symptomatic variables : PANSS scale

  4. Correlation of BOLD activity in the cortico-limbic circuit with emotional variables [5 days]

    emotional variables : ERS scale, ERQ scale, TAS-20 scale, SAS scale, AES-C scale

  5. Correlation of BOLD activity in the cortico-limbic circuit with personality characteristics [5 days]

    personality characteristics : EPQ-R scale, SPQ scale

  6. Correlation of BOLD activity in the cortico-limbic circuit with history of trauma in childhood [5 days]

    history of trauma in childhood : CTQ scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria of patients :
  • For women with reproductively active age period: suitable contraceptive method and negative pregnancy test

  • Schizophrenia diagnosis (according to DSM 5)

  • Regular follow-up care at hospital

  • No change in antipsychotic medication (medication AND dosage) within at least six weeks

  • Patient into remission : constant dosage, out-patient and meeting Andreassen criteria

  • Who have given their informed consent before participating in the study.

  • Physical examination without significant clinical physical anomaly

  • No serious somatic pathology

  • Affiliates or entitled to a social security scheme

Exclusion Criteria of patients :
  • For women with reproductively active age period: no suitable contraceptive method (oral, hormonal, intramuscular, intrauterine device, or surgical)

  • Pregnancy or breastfeeding

  • Not meeting schizophrenic criteria according to DSM 5 or presenting resistant schizophrenic criteria according Kane criteria

  • Presenting a serious somatic disorder or neurological (particularly Parkinson disease, epilepsy, tardive dyskinesia)

  • Cardiovascular, hepatic or serious renal diseases

  • Contraindication to MRI examination, particularly ocular or intracranial metallic foreign object,pacemaker, artificial heart valve, surgical clip

  • Claustrophobia, significant tatoo in the high part of the body, IUD incompatible with MRI 3Tesla

  • Alcohol or drug addiction, within the last year

  • Recruited in other clinical trial or exclusion period from previous trial.

  • Susceptibility to self-harm behaviour according to investigator

Inclusion Criteria of Related volunteers :
  • Age, gender and socio-educational level similar to recruited patients

  • Who have given their informed consent before participating in the study.

  • First degree relative of schizophrenic patient diagnosed according DSM IV criteria

  • No schizophrenia diagnosis according DSM IV criteria

  • No psychiatric history and free of psychotropic drugs/treatment

  • Physical examination without significant clinical anomaly

  • Affiliates or entitled to a social security scheme

Exclusion Criteria of Related volunteers :
  • For women with reproductively active age period: no suitable contraceptive method (oral, hormonal, intramuscular, intrauterine device, or surgical)

  • Pregnancy or breastfeeding

  • Presenting somatic, neurological or psychiatric disorder

  • Alcohol or drug addiction, within the last year

  • Recruited in other clinical trial or exclusion period from previous trial.

  • Contraindication to MRI examination, particularly ocular or intracranial metallic foreign object, pacemaker, artificial heart valve, surgical clip

  • Claustrophobia, significant tatoo in the high part of the body, IUD incompatible with MRI 3Tesla

Inclusion Criteria of Healthy volunteers :
  • Age, gender and socio-educational level similar to recruited patients

  • Who have given their informed consent before participating in the study.

  • No schizophrenia diagnosis according DSM IV criteria

  • No personal or family history of psychiatric disorders

  • Free of psychotropic drugs/treatment

  • Physical examination without significant clinical anomaly

  • Affiliates or entitled to a social security scheme

Exclusion Criteria of Healthy volunteers :

Beside the absence of schizophrenia diagnosis, healthy volunteers should meet the same exclusion criteria as patients

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Saint Etienne Saint-Étienne France 42055

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT03355781
Other Study ID Numbers:
  • 1608039
  • 2017-A00408-45
First Posted:
Nov 28, 2017
Last Update Posted:
Jan 19, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 19, 2021